Ensayo clínico multicéntrico, abierto, de fase II con doxorrubicina liposomal pegilada (Caelyx®) como tratamiento primario en pacientes con cáncer de mama y antecedentes de cardiopatía o con edad superior a 65 años
Juan Miguel Gil Gil, MD (Institut Català d'Oncologia - ICO Duran i Reynals)
Cookie | Duración | Descripción |
---|---|---|
_hjIncludedInSessionSample_2433519 | 2 minutes | Description is currently not available. |
FormsWebSessionId | 1 month | Description is currently not available. |
m | 1 year 1 month 4 days | No description available. |
MC1 | 1 year | No description available. |
RpsAuthNonce | 1 month | Description is currently not available. |
VISITOR_PRIVACY_METADATA | 5 months 27 days | Description is currently not available. |
Cookie | Duración | Descripción |
---|---|---|
_hjAbsoluteSessionInProgress | 30 minutes | Hotjar sets this cookie to detect a user's first pageview session, which is a True/False flag set by the cookie. |